Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Oleaga, Carlota ^a   Bernabini, Catia ^a   Smith, Alec S T ^a   Srinivasan, Balaji ^a   Jackson, Max ^a   McLamb, William ^a   Platt, Vivien ^a   Bridges, Richard ^a   Cai, Yunqing ^a   Santhanam, Navaneetha ^a   Berry, Bonnie ^a   Najjar, Sarah ^a   Akanda, Nesar ^a   Guo, Xiufang ^a   Martin, Candace ^a   Ekman, Gail ^a   Esch, Mandy B ^b   Langer, Jessica ^c   Ouedraogo, Gladys ^d   Cotovio, Jose ^d   Breton, Lionel ^d   Shuler, Michael L ^b   Hickman, James J ^a   more..

^a UNIVERSITY OF CENTRAL FLORIDA   (United States)

^b Cornell University   (United States)

^c L'Oreal Research and Innovation   (United States)

^d L ORÉAL RECHERCHE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SERUM-FREE MEDIUM;

BIOLOGICAL MODEL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL LINE; COCULTURE; CYTOLOGY; DRUG EFFECTS; HEP-G2 CELL LINE; HUMAN; INDUCED PLURIPOTENT STEM CELL; LAB ON A CHIP; LIVER; NERVE CELL; PRECLINICAL STUDY; PROCEDURES; SERUM-FREE MEDIUM; SKELETAL MUSCLE CELL;

CELL LINE; CELLS, CULTURED; COCULTURE TECHNIQUES; CULTURE MEDIA, SERUM-FREE; DRUG EVALUATION, PRECLINICAL; HEP G2 CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LAB-ON-A-CHIP DEVICES; LIVER; MODELS, BIOLOGICAL; MUSCLE FIBERS, SKELETAL; MYOCYTES, CARDIAC; NEURONS;

EID: 84957586265     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20030     Document Type: Article

References (68)

1. Wysowski, D. K., Swartz, L. Adverse drug event surveillance and drug withdrawals in the united states, 1969-2002: The importance of reporting suspected reactions. Arch. Intern. Med. 165, 1363-1369 (2005).
2. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., Rosenthal, J. Clinical development success rates for investigational drugs. Nat Biotech. 32, 40-51 (2014).
3. Esch, M. B. et al. How multi-organ microdevices can help foster drug development. Adv. Drug Deliv. Rev. 69-70, 158-169 (2014).
4. Huh, D., Torisawa, Y. S., Hamilton, G. A., Kim, H. J., Ingber, D. E. Microengineered physiological biomimicry: organs-on-chips. Lab Chip 12, 2156-2164 (2012).
5. Sung, J. H. et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 13, 1201-1212 (2013).
6. Lau, Y. Y. et al. Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. Drug Metab. Dispos. 32, 937-942 (2004).
7. Lee, M. Y. et al. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc. Natl. Acad. Sci. USA 105, 59-63 (2008).
8. Li, A. P., Bode, C., Sakai, Y. A novel in vitro system, the integrated discrete multiple organ cell culture (IdMOC) system, for the evaluation of human drug toxicity: comparative cytotoxicology of tamoxifen towards normal human cells from five major organs and MCF-7 adenocarcinoma breast cancer cells. Chem. Biol. Interact. 150, 129-136 (2004).
9. Wagner, I. et al. A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13, 3538-3547 (2013).
10. Iori, E. et al. Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo-and hyperglycaemia. PloS One 7, e34704 (2012).
11. Zhang, C., Zhao, A., Rahim, N. A. A., van Noort, D., Yu, H. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab Chip 9, 3185-3192 (2009).
12. Vozzi, F., Heinrich, J. M., Bader, A., Ahluwalia, A. D. Connected culture of murine hepatocytes and HUVEC in a multicompartmental bioreactor. Tissue Eng. Part A 15, 1291-1299 (2009).
13. van der Valk, J. et al. Optimization of chemically defined cell culture media-replacing fetal bovine serum in mammalian in vitro methods. Toxicol. In Vitro 24, 1053-1063 (2010).
14. Sung, J. H., Kam, C., Shuler, M. L. A microfludic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10, 446-455 (2010).
15. Esch, M. B., Mahler, G. J., Stokol, T., Shuler, M. L. Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that ingested nanoparticles have the potential to cause liver injury. Lab Chip 14, 3081-3092 (2014).
16. Pirozzi, K., Long, C. J., McAleer, C. W., Smith, A. S. T., Hickman, J. J. Correlation of embryonic skeletal muscle myotube physical characteristics with contractile force generation on an atomic force microscope-based biomicroelectromechanical systems device. Appl. Phys. Lett. 103, 083108 (2013).
17. Carvalho, C. et al. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 16, 3267-3285 (2009).
18. Ginanneschi, F. et al. Rhabdomyolysis in an elderly multitreated patient: multiple drug interactions after statin withdrawal. J. Neurol. Sci. 336, 284-287 (2014).
19. Skottheim, I. B., Gedde-Dahl, A., Hejazifar, S., Hoel, K., Asberg, A. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur. J. Pharm. Sci. 33, 317-325 (2008).
20. Lins, R. L. et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol. Dial. Transplant. 18, 967-976 (2003).
21. Valera, H. R., Ganguly, B. Study of plasma level of atorvastatin and its effect on lipid profile. Indian J. Physiol. Pharmacol. 53, 73-82 (2009).
22. Loscher, W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16, 669-694 (2002).
23. Duenas-Gonzalez, A. et al. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 34, 206-222 (2008).
24. Chateauvieux, S., Morceau, F., Dicato, M., Diederich, M. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. 2010, 479364 (2010).
25. Blough, E. R., Wu, M. Acetaminophen: beyond pain and Fever-relieving. Front. Pharmacol. 2, 72 (2011).
26. Hadzimichalis, N. M. et al. Acetaminophen-mediated cardioprotection via inhibition of the mitochondrial permeability transition pore-induced apoptotic pathway. Am. J. Physiol. Heart Circ. Physiol. 293, H3348-3355 (2007).
27. Montgomery, C. J., McCormack, J. P., Reichert, C. C., Marsland, C. P. Plasma concentrations after high-dose (45 mg.kg?1) rectal acetaminophen in children. Can. J. Anaesth. 42, 982-986 (1995).
28. Rumack, B. H., Matthew, H. Acetaminophen poisoning and toxicity. Pediatrics 55, 871-876 (1975).
29. Hannoun, Z. et al. The comparison between conditioned media and serum-free media in human embryonic stem cell culture and differentiation. Cell Reprogram. 12, 133-140 (2010).
30. Klein, S., Mueller, D., Schevchenko, V., Naar, F. Long-term maintenance of HepaRG cells in serum-free conditions and application in a repeated dose study. J. Appl. Toxicol. 34, 1078-1086 (2014).
31. Roberts, S. M., James, R. C., Williams, P. L. Principles of Toxicology: Environmental and Industrial Applications. 3 edn, (John Wiley & Sons, 2015).
32. Horner, S., Robinson, S., Lees, D., Callander, R., Roberts, R. Target organ profiles in toxicity studies supporting human dosing: An assessment of recovery and chronic dosing. Regul. Toxicol. Pharmacol. 70, 270-285 (2014).
33. Szkolnicka, D. et al. Accurate prediction of drug-induced liver injury using stem cell-derived populations. Stem Cells Transl. Med. 3, 141-148 (2014).
34. Clements, M., Millar, V., Williams, A., Kalinka, S. Bridging functional and structural cardiotoxicity assays using human embryonic stem-cell derived cardiomyocytes for a more comprehensive risk assessment. Toxicol. Sci. 148, 241-260 (2015).
35. Raschi, E., Ceccarini, L., De Ponti, F., Recanatini, M. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opin. Drug Metab. Toxicol. 5, 1005-1021 (2009).
36. Torres, V. M., Simic, V. D. in Cardiotoxicity of oncologic treatments (ed M. Fiuza) Ch. 5, (InTech, 2012).
37. Abassi, Y. A. et al. Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-1441 (2012).
38. Cusack, B. J., Young, S. P., Driskell, J., Olson, R. D. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother. Pharmacol. 32, 53-58 (1993).
39. Olson, R. D. et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc. Natl. Acad. Sci. USA 85, 3585-3589 (1988).
40. Damodar, G., Smitha, T., Gopinath, S., Vijayakumar, S., Rao, Y. An evaluation of hepatotoxicity in breast cancer patients receiving injection Doxorubicin. Ann. Med. Health Sci. Res. 4, 74-79 (2014).
41. Aquilano, K. et al. Neuronal nitric oxide synthase protects neuroblastoma cells from oxidative stress mediated by garlic derivatives. J. Neurochem. 101, 1327-1337 (2007).
42. Gilliam, L. A. et al. Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J. Appl. Physiol. 107, 1935-1942 (2009).
43. van Norren, K. et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br. J. Cancer 100, 311-314 (2009).
44. Clarke, A. T., Mills, P. R. Atorvastatin associated liver disease. Dig. Liver Dis. 38, 772-777 (2006).
45. Gershovich, O. E., Lyman, A. E. Jr. Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature. Pharmacotherapy 24, 150-154 (2004).
46. Liu, Y. et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int. J. Clin. Pharmacol. Ther. 48, 798-802 (2010).
47. Ramanjaneyulu, S. V., Trivedi, P. P., Kushwaha, S., Vikram, A., Jena, G. B. Protective role of atorvastatin against doxorubicininduced cardiotoxicity and testicular toxicity in mice. J. Physiol. Biochem. 69, 513-525 (2013).
48. Bösel, J. et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 92, 1386-1398 (2005).
49. Wood, W. G., Eckert, G. P., Igbavboa, U., Muller, W. E. Statins and neuroprotection: a prescription to move the field forward. Ann. N. Y. Acad. Sci. 1199, 69-76 (2010).
50. Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102-146 (2012).
51. Mailman, T., Hariharan, M., Karten, B. Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J. Neurochem. 119, 1002-1015 (2011).
52. Li, X. et al. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells. Biochem. Biophys. Res. Commun. 436, 259-264 (2013).
53. Schuchmann, M. et al. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95-and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol. Rep. 15, 227-230 (2006).
54. Knapp, A. C. et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. J. Pharmacol. Exp. Ther. 324, 568-575 (2008).
55. Lee, J. Y. et al. Valproic acid protects motor neuron death by inhibiting oxidative stress and endoplasmic reticulum stress-mediated cytochrome C release after spinal cord injury. J. Neurotrauma 31, 582-594 (2014).
56. Lee, T. M., Lin, M. S., Chang, N. C. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. American journal of physiology. Am. J. Physiol. Heart Circ. Physiol. 293, H968-977 (2007).
57. Bessems, J. G., Vermeulen, N. P. Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms, analogues and protective approaches. Crit. Rev. Toxicol. 31, 55-138 (2001).
58. McGill, M. R. et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest. 122, 1574-1583 (2012).
59. Ma, B., Zhang, G., Qin, J., Lin, B. Characterization of drug metabolites and cytotoxicity assay simultaneously using an integrated microfluidic device. Lab Chip 9, 232-238 (2009).
60. Holme, J. A., Hongslo, J. K., Bjorge, C., Nelson, S. D. Comparative cytotoxic effects of acetaminophen (N-acetyl-p-aminophenol), a non-hepatotoxic regioisomer acetyl-m-aminophenol and their postulated reactive hydroquinone and quinone metabolites in monolayer cultures of mouse hepatocytes. Biochem. Pharmacol. 42, 1137-1142 (1991).
61. Kenna, J. G. A new twist to an old tale: novel insights into the differential toxicities of acetaminophen and its regioisomer N-acetylmeta-aminophenol (AMAP). Arch. Toxicol. 87, 15-18 (2013).
62. Myers, T. G. et al. A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3?-hydroxyacetanilide. Chem. Res. Toxicol. 8, 403-413 (1995).
63. Natarajan, A. et al. Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform. Biomaterials 32, 4267-4274 (2011).
64. Guo, X. et al. In vitro differentiation of functional human skeletal myotubes in a defined system. Biomater. Sci. 2, 131-138 (2014).
65. Powell, C. et al. Tissue engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum. Gene Ther. 10, 565-577 (1999).
66. Guo, X. F., Johe, K., Molnar, P., Davis, H., Hickman, J. J. Characterization of a human fetal spinal cord stem cell line NSI-566RSC and its induction to functional motoneurons. J. Tissue Eng. Regen. Med. 4, 181-193 (2010).
67. Guo, X., Gonzalez, M., Stancescu, M., Vandenburgh, H., Hickman, J. J. Neuromuscular junction formation between human stem cell-derived motoneurons and human skeletal muscle in a defined system. Biomaterials 32, 9602-9611 (2011).
68. Edwards, D., Das, M., Molnar, P., Hickman, J. J. Addition of glutamate to serum free culture improves the electrical properties of adult hippocampal neurons in vitro. J. Neurosci. Methods 190, 155-163 (2010).